DNA vaccine candidate for Lassa fever: First subject dosed in Phase 1B Clinical Trial
by Press Release from Outbreak News Today on (#5EJMM)
Biotechnology company, INOVIO, announced the first participant was dosed in a Phase 1B clinical trial for INO-4500, its DNA vaccine candidate for Lassa fever, in Ghana. The Phase 1B clinical trial (LSV-002), ongoing at the Noguchi Memorial Institute for Medical Research in Accra, Ghana, is the first vaccine clinical trial for Lassa fever to be conducted in West Africa, where the infection [...]
The post DNA vaccine candidate for Lassa fever: First subject dosed in Phase 1B Clinical Trial appeared first on Outbreak News Today.